High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer

Ma,Xiaoming; Du,Tao; Zhu,Dingjun; Chen,Xianju; Lai,Yiming; Wu,Wanhua; Wang,Qiong; Lin,Chunhao; Li,Zean; Liu,Leyuan; Huang,Hai

doi:10.3892/ol.2018.9490

High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer

Authors:
- Xiaoming Ma
- Tao Du
- Dingjun Zhu
- Xianju Chen
- Yiming Lai
- Wanhua Wu
- Qiong Wang
- Chunhao Lin
- Zean Li
- Leyuan Liu
- Hai Huang
View Affiliations

Affiliations: Department of Urology, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat‑Sen Memorial Hospital, Sun Yat‑Sen University, Guangzhou, Guangdong 510120, P.R. China, Center for Translational Cancer Research, Texas A&M Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA
Published online on: September 24, 2018 https://doi.org/10.3892/ol.2018.9490
Pages: 6749-6755

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma tumor suppressor candidate region gene 1 (GLTSCR1) is associated with the progression of oligodendroglioma. However, there has been little study of GLTSCR1 in prostate cancer. In the present study, the association between the expression of GLTSCR1, and the progression and prognosis of tumors in patients with prostate cancer was assessed. An immunohistochemical analysis was performed using a human tissue microarray for GLTSCR1 at the protein expression level and the immunostaining results were evaluated against clinical variables of patients with prostate cancer. Subsequently, The Cancer Genome Atlas (TCGA) was used to validate the analysis results at the mRNA level and to study the prognostic value of GLTSCR1 in prostate cancer. Immunohistochemistry and TCGA data analysis revealed that GLTSCR1 expression in the prostate cancer tissues was significantly higher than that in the benign prostate tissues (immunoreactivity score, P=0.015; mRNA levels: cancer, 447.7±6.45 vs. benign, 343.5±4.21; P<0.001). Additionally, the increased GLTSCR1 protein expression was associated with certain clinical variables in the prostate cancer tissues, including advanced clinical stage (P<0.001), enhanced tumor invasion (P=0.003), lymph node metastasis (P=0.003) and distant metastasis (P=0.001). TCGA data revealed similar results, demonstrating that the upregulation of GLTSCR1 mRNA expression was associated with the Gleason score (P<0.001), enhanced tumor invasion (P=0.011), lymph node metastasis (P=0.001) and distant metastasis (P=0.002). Furthermore, Kaplan‑Meier analysis suggested that among all patients, high GLTSCR1 expression indicated a decreased overall survival (P=0.028) and biochemical recurrence (BCR)‑free survival (P=0.004), compared with patients with low GLTSCR1 expression. Finally, multivariate analysis revealed that the expression of GLTSCR1 was an independent predictor of poor BCR‑free survival (P=0.049). The present study suggested that the increased expression of GLTSCR1 was associated with the progression of prostate cancer. Furthermore, GLTSCR1 may be a novel biomarker that is able to predict the clinical outcome in prostate cancer patients.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol. 61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
4	Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al: Prevention and early detection of prostate cancer. Lancet Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
5	Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F and Karakiewicz PI: Survival benefit of radical prostatectomy in patients with localized prostate cancer: Estimations of the number needed to treat according to tumor and patient characteristics. J Urol. 188:73–83. 2012. View Article : Google Scholar : PubMed/NCBI
6	Molitierno J, Evans A, Mohler JL, Wallen E, Moore D and Pruthi RS: Characterization of biochemical recurrence after radical prostatectomy. Urol Int. 77:130–134. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shariat SF, Karakiewicz PI, Roehrborn CG and Kattan MW: An updated catalog of prostate cancer predictive tools. Cancer. 113:3075–3099. 2008. View Article : Google Scholar : PubMed/NCBI
8	Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA and Kattan MW: Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 23:7005–7012. 2005. View Article : Google Scholar : PubMed/NCBI
9	Lilja H, Ulmert D and Vickers AJ: Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer. 8:268–278. 2008. View Article : Google Scholar : PubMed/NCBI
10	Velonas VM, Woo HH, dos Remedios CG and Assinder SJ: Current status of biomarkers for prostate cancer. Int J Mol Sci. 14:11034–11060. 2013. View Article : Google Scholar : PubMed/NCBI
11	Liu L, McKeehan WL, Wang F and Xie R: MAP1S enhances autophagy to suppress tumorigenesis. Autophagy. 8:278–280. 2012. View Article : Google Scholar : PubMed/NCBI
12	Jiang X, Zhong W, Huang H, He H, Jiang F, Chen Y, Yue F, Zou J, Li X, He Y, et al: Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients. Mol Carcinog. 54:1194–1204. 2015. View Article : Google Scholar : PubMed/NCBI
13	Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, Portier BP, Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, et al: A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 64:44–50. 2000. View Article : Google Scholar : PubMed/NCBI
14	Yang P, Kollmeyer TM, Buckner K, Bamlet W, Ballman KV and Jenkins RB: Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer. 103:2363–2372. 2005. View Article : Google Scholar : PubMed/NCBI
15	Neville PJ, Conti DV, Krumroy LM, Catalona WJ, Suarez BK, Witte JS and Casey G: Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer. 36:332–339. 2003. View Article : Google Scholar : PubMed/NCBI
16	Slager SL, Schaid DJ, Cunningham JM, McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S, French AJ and Thibodeau SN: Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet. 72:759–762. 2003. View Article : Google Scholar : PubMed/NCBI
17	Epstein JI, Feng Z, Trock BJ and Pierorazio PM: Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: Incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 61:1019–1024. 2012. View Article : Google Scholar : PubMed/NCBI
18	Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI
19	Xie ZC, Li TT, Gan BL, Gao X, Gao L, Chen G and Hu XH: Investigation of miR-136-5p key target genes and pathways in lung squamous cell cancer based on TCGA database and bioinformatics analysis. Pathol Res Pract. 214:644–654. 2018. View Article : Google Scholar : PubMed/NCBI
20	Guo Z, Chen X, Du T, Zhu D, Lai Y, Dong W, Wu W, Lin C, Liu L and Huang H: Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer. Med Oncol. 34:132017. View Article : Google Scholar : PubMed/NCBI
21	Zhang KX, Firus J, Prieur B, Jia W and Rennie PS: To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy. Cancers (Basel). 3:1498–1512. 2011. View Article : Google Scholar : PubMed/NCBI
22	Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW and Howley PM: The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol. 31:2641–2652. 2011. View Article : Google Scholar : PubMed/NCBI
23	Adam K, Lambert M, Lestang E, Champenois G, Dusanter-Fourt I, Tamburini J, Bouscary D, Lacombe C, Zermati Y and Mayeux P: Control of Pim2 kinase stability and expression in transformed human haematopoietic cells. Biosci Rep. 35:e002742015. View Article : Google Scholar : PubMed/NCBI
24	Xu J, Zhang T, Wang T, You L and Zhao Y: PIM kinases: An overview in tumors and recent advances in pancreatic cancer. Future Oncol. 10:865–876. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yu Z, Zhao X, Huang L, Zhang T, Yang F, Xie L, Song S, Miao P, Zhao L, Sun X, et al: Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells. J Biol Chem. 288:35406–35416. 2013. View Article : Google Scholar : PubMed/NCBI
26	Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z and He W: The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B. Prostate. 73:1462–1469. 2013. View Article : Google Scholar : PubMed/NCBI
27	Bohensky J, Shapiro IM, Leshinsky S, Watanabe H and Srinivas V: PIM-2 is an independent regulator of chondrocyte survival and autophagy in the epiphyseal growth plate. J Cell Physiol. 213:246–251. 2007. View Article : Google Scholar : PubMed/NCBI
28	Amaravadi R, Kimmelman AC and White E: Recent insights into the function of autophagy in cancer. Genes Dev. 30:1913–1930. 2016. View Article : Google Scholar : PubMed/NCBI